Other regimens included radiation as monotherapy (IDH-wt astrocytoma: 4 (2.5%); IDH-wt glioblastoma: 16 (7.9%)), Nordic radiation scheme (IDH-wt astrocytoma: 0 (-); IDH-wt glioblastoma: 4 (2.0%)) and best-supportive care. The gene discussed is IDH2; the disease is glioblastoma.